Kocfa Chung-Delgado
Overview
Explore the profile of Kocfa Chung-Delgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopalco P, Esposito S, Martinon-Torres F, Lisi G, Chung-Delgado K, Davidson B, et al.
J Prev Med Hyg
. 2024 Feb;
64(4):E377-E381.
PMID: 38379744
Introduction: The language of medicine is constantly evolving, typically to better describe a new understanding of disease, adjust to changing social sensibilities, or simply to reflect a new drug class...
2.
Chung-Delgado K, Valdivia Venero J, Vu T
Cureus
. 2021 Apr;
13(3):e14105.
PMID: 33907645
Understanding the determinants of vaccine hesitancy is paramount to reinstate confidence in immunizations. The objective of this investigation was to explore the characteristics of the vaccination decision-making process that may...
3.
Montesinos-Segura R, Maticorena-Quevedo J, Chung-Delgado K, Pereyra-Elias R, Taype-Rondan A, Mayta-Tristan P
Rural Remote Health
. 2018 May;
18(2):4331.
PMID: 29734813
Introduction: Health professionals performing their social health service (SHS) in rural communities could be at risk of developing depression. Moreover, those who migrate from farther places to perform their SHS...
4.
Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A
PLoS One
. 2015 Mar;
10(3):e0119332.
PMID: 25790076
Background: An increase in multidrug-resistant tuberculosis (MDR-TB) cases is evident worldwide. Its management implies a complex treatment, high costs, more toxic anti-tuberculosis drug use, longer treatment time and increased treatment...
5.
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Bernabe-Ortiz A
Int J Infect Dis
. 2014 Mar;
23:20-4.
PMID: 24657270
Objectives: We aimed to assess the variation in patient body weight over time according to the treatment outcome among multidrug-resistant tuberculosis (MDR-TB) cases. Methods: This was a retrospective cohort study....
6.
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Rios-Diaz H, Alva-Munoz J
Case Rep Hematol
. 2013 Aug;
2013:391086.
PMID: 23984123
A 37-year-old woman with history of Evans Syndrome with poor response to high-dose corticoid treatment presented to the emergency department with gastrointestinal and vaginal bleeding. The patient was later diagnosed...
7.
Chung-Delgado K, Guillen-Bravo S, Navarro-Huaman L, Quiroz-Portella R, Revilla-Montag A, Ruiz-Alejos A, et al.
Rev Chilena Infectol
. 2012 Oct;
29(4):375-81.
PMID: 23096535
Introduction: One third of the world population is affected by latent tuberculosis, with 9.4 million new cases; medical students have 2 to 50 times the probability of acquiring the infection....
8.
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nunez-Garbin A, et al.
PLoS One
. 2011 Nov;
6(11):e27610.
PMID: 22110689
Background: Long-term exposure to anti-tuberculosis medication increases risk of adverse drug reactions and toxicity. The objective of this investigation was to determine factors associated with anti-tuberculosis adverse drug reactions in...